Sodium thiosulfate to protect hearing in medulloblastoma
Treatments studied
Part of Cancer clinical trials.
This Phase 3 study tests whether adding sodium thiosulfate during treatment for newly diagnosed medulloblastoma can reduce the risk of hearing loss. It is designed for children and teens whose cancer meets specific low-risk or average-risk tumor and lab features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 4 to 21 at enrollment
- Have a new (just diagnosed) medulloblastoma confirmed by special central pathology and molecular testing
- Have MRI scans that show no spread to other parts of the brain or spine (no metastasis)
- Have a spinal fluid (lumbar CSF) test that is negative for cancer cells
- Have hearing that is normal in at least one ear (checked by a central audiology review)
- Be able to meet study timing and blood/organ health checks (including enough weight and blood counts, and kidney/liver lab limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two standard treatment plans for young children with a specific type of medulloblastoma (a brain tumor). It looks at how each treatment affects thinking and learning over time, to see which one helps children do better in the long run.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This program provides access to sodium thiosulfate (STS) for children with hepatoblastoma who are receiving cisplatin chemotherapy. The drug may help protect the kidneys from cisplatin's side effects, and the goal is to give patients a chance to benefit from this treatment.
This trial tests whether a medicine called sodium thiosulfate can protect your hearing from the side effects of cisplatin chemotherapy. It is for people with newly diagnosed cancer who are about to receive cisplatin for the first time.
This trial tests whether adding Pedmark (sodium thiosulfate) to cisplatin chemotherapy can protect hearing in men with stage II or III testicular germ cell tumors. It aims to reduce the risk of drug-related ear damage while still treating the cancer.
This Phase 2 trial tests whether sodium thiosulfate and mannitol can reduce hearing damage (ototoxicity) in adults receiving cisplatin chemotherapy. It may help protect hearing while you get cancer treatment.
Hear when a new Childhood Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.